Uses and abuses of fresh-frozen plasma for the prophylaxis of bleeding

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 13, Issue 2, 2013, Pages 197-199

  Desborough, M J ^a   Stanworth, S J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ACUTE LUNG INJURY; ALLERGIC REACTION; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 12 DEFICIENCY; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; BRONCHOSCOPY; CLINICAL PRACTICE; CRITICALLY ILL PATIENT; HUMAN; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); THROMBIN TIME; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; PLASMA; PRACTICE GUIDELINE; TREATMENT OUTCOME;

BLEEDING; COAGULOPATHY; FRESH FROZEN PLASMA;

BLOOD COAGULATION TESTS; BLOOD COMPONENT TRANSFUSION; HEMORRHAGE; HUMANS; PLASMA; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84884528507     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.13-2-197     Document Type: Article

References (13)

1. Desborough MJ, Stanworth SJ, Curry NS. Uses and abuses of fresh frozen plasma for the treatment of bleeding. Clin Med 2013;13:xxx-xxx.
2. Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep 2004;3:324-30.
3. Burns ER, Goldberg SN, Wenz B. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin Pathol 1993;100:94-8.
4. Callum JL, Dzik WH. The use of blood components prior to invasive bedside procedures: A critical appraisal. In: Mintz PD (ed), Transfusion therapy: clinical principles and practice, 3rd edn. Bethesda: AABB Press, 2010:1-35.
5. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005;45:1413-25.
6. Stanworth SJ, Grant-Casey J, Lowe D et al. The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion 2011;51:62-70.
7. Stanworth SJ, Walsh TS, Prescott RJ et al. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Crit Care 2011;15:R108.
8. Yang L, Stanworth S, Hopewell S et al. Is fresh frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion 2012;52:1673-86.
9. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012;52:160-5.
10. Toy P, Gajic O, Bacchetti P et al. Transfusion related acute lung injury: incidence and risk factors. Blood 2012;119:1757-67.
11. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009;49:14-23.
12. O' Shaughnessy DF, Atterbury C, Bolton- Maggs P et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004;126:11-28.
13. Lipworth W, Kerridge I, Little M et al. Evidence and desperation in off-label prescribing: recombinant factor VIIa. BMJ 2012;344:d7926.